Build Your Comparison

Side-by-side financial analysis
VSTM logo
VSTM
TGTX logo
TGTX
JPM logo
JPM
KO logo
KO
Try popular comparisons:

Stock Comparison

VSTM vs TGTX vs JPM vs KO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
VSTM
Verastem, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$284M
5Y Perf.-80.1%
TGTX
TG Therapeutics, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$7.58B
5Y Perf.+154.2%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$896.00B
5Y Perf.+241.0%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.61B
5Y Perf.+84.9%

VSTM vs TGTX vs JPM vs KO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
VSTM logoVSTM
TGTX logoTGTX
JPM logoJPM
KO logoKO
IndustryBiotechnologyBiotechnologyBanks - DiversifiedBeverages - Non-Alcoholic
Market Cap$284M$7.58B$896.00B$355.61B
Revenue (TTM)$50M$700M$280.33B$49.28B
Net Income (TTM)$-194M$462M$57.05B$13.70B
Gross Margin83.7%83.0%60.0%61.7%
Operating Margin-344.6%21.3%25.9%29.3%
Forward P/E35.9x14.4x25.3x
Total Debt$77M$261M$942.38B$45.49B
Cash & Equiv.$205M$79M$343.34B$10.27B

VSTM vs TGTX vs JPM vs KOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

VSTM
TGTX
JPM
KO
StockJun 20Jun 26Return
Verastem, Inc. (VSTM)10019.9-80.1%
TG Therapeutics, In… (TGTX)100254.2+154.2%
JPMorgan Chase & Co. (JPM)100341.0+241.0%
The Coca-Cola Compa… (KO)100184.9+84.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: VSTM vs TGTX vs JPM vs KO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: TGTX leads in 4 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Verastem, Inc. is the stronger pick specifically for growth and revenue expansion. JPM and KO also each lead in at least one category. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
🥇TGTX emerged as the overall leader. Track its performance:
VSTM
Verastem, Inc.
The Growth Leader

VSTM is the #2 pick in this set and the best alternative if growth is your priority.

  • 209.1% revenue growth vs KO's 1.9%
Best for: growth
TGTX
TG Therapeutics, Inc.
The Growth Play

TGTX carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.

  • Rev growth 87.3%, EPS growth 17.5%, 3Y rev CAGR 5.0%
  • Lower volatility, beta 0.65, Low D/E 40.2%, current ratio 4.10x
  • Beta 0.65, current ratio 4.10x
  • 66.0% margin vs VSTM's -391.2%
Best for: growth exposure and sleep-well-at-night
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM is the clearest fit if your priority is long-term compounding and valuation efficiency.

  • 465.8% 10Y total return vs TGTX's 6.1%
  • PEG 0.81 vs KO's 2.26
  • Lower P/E (14.4x vs 25.3x), PEG 0.81 vs 2.26
Best for: long-term compounding and valuation efficiency
KO
The Coca-Cola Company
The Income Pick

KO is the clearest fit if your priority is income & stability.

  • Dividend streak 56 yrs, beta -0.20, yield 2.5%
  • 2.5% yield, 56-year raise streak, vs JPM's 1.9%, (2 stocks pay no dividend)
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthVSTM logoVSTM209.1% revenue growth vs KO's 1.9%
ValueJPM logoJPMLower P/E (14.4x vs 25.3x), PEG 0.81 vs 2.26
Quality / MarginsTGTX logoTGTX66.0% margin vs VSTM's -391.2%
Stability / SafetyTGTX logoTGTXBeta 0.65 vs VSTM's 1.64, lower leverage
DividendsKO logoKO2.5% yield, 56-year raise streak, vs JPM's 1.9%, (2 stocks pay no dividend)
Momentum (1Y)TGTX logoTGTX+32.5% vs VSTM's -30.3%
Efficiency (ROA)TGTX logoTGTX42.8% ROA vs VSTM's -91.6%

VSTM vs TGTX vs JPM vs KO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

VSTMVerastem, Inc.
FY 2025
Government rebates and other incentives
77.7%$4M
Trade discounts and allowances
15.7%$888,000
Returns
6.6%$376,000
TGTXTG Therapeutics, Inc.
FY 2025
Product
98.5%$607M
Royalty
0.9%$6M
Other Revenue
0.6%$4M
License Revenue
0.0%$152,000
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B

VSTM vs TGTX vs JPM vs KO — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLTGTXLAGGINGVSTM

Income & Cash Flow (Last 12 Months)

TGTX leads this category, winning 3 of 6 comparable metrics.

JPM is the larger business by revenue, generating $280.3B annually — 5653.6x VSTM's $50M. TGTX is the more profitable business, keeping 66.0% of every revenue dollar as net income compared to VSTM's -3.9%. On growth, TGTX holds the edge at +69.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricVSTM logoVSTMVerastem, Inc.TGTX logoTGTXTG Therapeutics, …JPM logoJPMJPMorgan Chase & …KO logoKOThe Coca-Cola Com…
RevenueTrailing 12 months$50M$700M$280.3B$49.3B
EBITDAEarnings before interest/tax-$170M$150M$81.4B$15.5B
Net IncomeAfter-tax profit-$194M$462M$57.0B$13.7B
Free Cash FlowCash after capex-$151M-$14M$100.9B$12.6B
Gross MarginGross profit ÷ Revenue+83.7%+83.0%+60.0%+61.7%
Operating MarginEBIT ÷ Revenue-3.4%+21.3%+25.9%+29.3%
Net MarginNet income ÷ Revenue-3.9%+66.0%+20.4%+27.8%
FCF MarginFCF ÷ Revenue-3.0%-2.0%+36.0%+25.5%
Rev. Growth (YoY)Latest quarter vs prior year+69.6%+12.1%
EPS Growth (YoY)Latest quarter vs prior year+61.5%+2.9%+16.0%+18.2%
TGTX leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

JPM leads this category, winning 6 of 7 comparable metrics.

At 16.0x trailing earnings, JPM trades at a 41% valuation discount to KO's 27.2x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.90x vs KO's 2.43x — a lower PEG means you pay less per unit of expected earnings growth.

MetricVSTM logoVSTMVerastem, Inc.TGTX logoTGTXTG Therapeutics, …JPM logoJPMJPMorgan Chase & …KO logoKOThe Coca-Cola Com…
Market CapShares × price$284M$7.6B$896.0B$355.6B
Enterprise ValueMkt cap + debt − cash$156M$7.8B$1.50T$390.8B
Trailing P/EPrice ÷ TTM EPS-1.36x17.88x16.00x27.18x
Forward P/EPrice ÷ next-FY EPS est.35.88x14.40x25.27x
PEG RatioP/E ÷ EPS growth rate0.90x2.43x
EV / EBITDAEnterprise value multiple62.82x18.36x26.39x
Price / SalesMarket cap ÷ Revenue9.19x12.30x3.20x7.42x
Price / BookPrice ÷ Book value/share4.97x12.33x2.47x10.40x
Price / FCFMarket cap ÷ FCF8.88x67.15x
JPM leads this category, winning 6 of 7 comparable metrics.

Profitability & Efficiency

TGTX leads this category, winning 5 of 9 comparable metrics.

TGTX delivers a 87.4% return on equity — every $100 of shareholder capital generates $87 in annual profit, vs $-5 for VSTM. TGTX carries lower financial leverage with a 0.40x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs TGTX's 4/9, reflecting strong financial health.

MetricVSTM logoVSTMVerastem, Inc.TGTX logoTGTXTG Therapeutics, …JPM logoJPMJPMorgan Chase & …KO logoKOThe Coca-Cola Com…
ROE (TTM)Return on equity-4.9%+87.4%+15.9%+41.1%
ROA (TTM)Return on assets-91.6%+42.8%+1.3%+13.1%
ROICReturn on invested capital+16.4%+4.5%+15.8%
ROCEReturn on capital employed-139.0%+17.7%+8.9%+17.3%
Piotroski ScoreFundamental quality 0–94457
Debt / EquityFinancial leverage1.34x0.40x2.60x1.33x
Net DebtTotal debt minus cash-$128M$182M$599.0B$35.2B
Cash & Equiv.Liquid assets$205M$79M$343.3B$10.3B
Total DebtShort + long-term debt$77M$261M$942.4B$45.5B
Interest CoverageEBIT ÷ Interest expense-208.73x5.67x0.74x10.70x
TGTX leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — TGTX and JPM each lead in 3 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $722 for VSTM. Over the past 12 months, TGTX leads with a +32.5% total return vs VSTM's -30.3%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.6% vs VSTM's -25.4% — a key indicator of consistent wealth creation.

MetricVSTM logoVSTMVerastem, Inc.TGTX logoTGTXTG Therapeutics, …JPM logoJPMJPMorgan Chase & …KO logoKOThe Coca-Cola Com…
YTD ReturnYear-to-date-43.3%+69.1%-0.5%+20.3%
1-Year ReturnPast 12 months-30.3%+32.5%+21.8%+17.2%
3-Year ReturnCumulative with dividends-58.5%+89.0%+138.2%+47.0%
5-Year ReturnCumulative with dividends-92.8%+29.3%+118.2%+65.6%
10-Year ReturnCumulative with dividends-75.2%+605.4%+465.8%+121.1%
CAGR (3Y)Annualised 3-year return-25.4%+23.6%+33.6%+13.7%
Evenly matched — TGTX and JPM each lead in 3 of 6 comparable metrics.

Risk & Volatility

KO leads this category, winning 2 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than VSTM's 1.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs VSTM's 36.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricVSTM logoVSTMVerastem, Inc.TGTX logoTGTXTG Therapeutics, …JPM logoJPMJPMorgan Chase & …KO logoKOThe Coca-Cola Com…
Beta (5Y)Sensitivity to S&P 5001.64x0.65x0.94x-0.20x
52-Week HighHighest price in past year$11.25$50.41$337.25$84.04
52-Week LowLowest price in past year$3.55$25.28$262.71$65.35
% of 52W HighCurrent price vs 52-week peak+36.4%+98.2%+95.1%+98.3%
RSI (14)Momentum oscillator 0–10039.776.159.160.6
Avg Volume (50D)Average daily shares traded2.1M2.0M7.0M12.7M
KO leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

KO leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: VSTM as "Buy", TGTX as "Buy", JPM as "Buy", KO as "Buy". Consensus price targets imply 345.1% upside for VSTM (target: $18) vs 4.2% for KO (target: $86). For income investors, KO offers the higher dividend yield at 2.46% vs JPM's 1.86%.

MetricVSTM logoVSTMVerastem, Inc.TGTX logoTGTXTG Therapeutics, …JPM logoJPMJPMorgan Chase & …KO logoKOThe Coca-Cola Com…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$18.25$54.50$339.75$86.13
# AnalystsCovering analysts19136148
Dividend YieldAnnual dividend ÷ price+1.9%+2.5%
Dividend StreakConsecutive years of raises01556
Dividend / ShareAnnual DPS$5.95$2.04
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.2%+3.9%+0.2%
KO leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

TGTX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). KO leads in 2 (Risk & Volatility, Analyst Outlook). 1 tied.

Best OverallTG Therapeutics, Inc. (TGTX)Leads 2 of 6 categories
Loading custom metrics...

VSTM vs TGTX vs JPM vs KO: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is VSTM or TGTX or JPM or KO a better buy right now?

For growth investors, Verastem, Inc.

(VSTM) is the stronger pick with 209. 1% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Verastem, Inc. (VSTM) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — VSTM or TGTX or JPM or KO?

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus The Coca-Cola Company at 27. 2x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus The Coca-Cola Company's 2. 26x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — VSTM or TGTX or JPM or KO?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -92. 8% for Verastem, Inc. (VSTM). Over 10 years, the gap is even starker: TGTX returned +605. 4% versus VSTM's -75. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — VSTM or TGTX or JPM or KO?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Verastem, Inc. 's 1. 64β — meaning VSTM is approximately -918% more volatile than KO relative to the S&P 500. On balance sheet safety, TG Therapeutics, Inc. (TGTX) carries a lower debt/equity ratio of 40% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — VSTM or TGTX or JPM or KO?

By revenue growth (latest reported year), Verastem, Inc.

(VSTM) is pulling ahead at 209. 1% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: TG Therapeutics, Inc. grew EPS 1747% year-over-year, compared to 1. 5% for JPMorgan Chase & Co.. Over a 3-year CAGR, TGTX leads at 504. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — VSTM or TGTX or JPM or KO?

TG Therapeutics, Inc.

(TGTX) is the more profitable company, earning 72. 6% net margin versus -677. 6% for Verastem, Inc. — meaning it keeps 72. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -550. 3% for VSTM. At the gross margin level — before operating expenses — TGTX leads at 83. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is VSTM or TGTX or JPM or KO more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 4x forward P/E versus 35. 9x for TG Therapeutics, Inc. — 21. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VSTM: 345. 1% to $18. 25.

08

Which pays a better dividend — VSTM or TGTX or JPM or KO?

In this comparison, KO (2.

5% yield), JPM (1. 9% yield) pay a dividend. VSTM, TGTX do not pay a meaningful dividend and should not be held primarily for income.

09

Is VSTM or TGTX or JPM or KO better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Verastem, Inc. (VSTM) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, VSTM: -75. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between VSTM and TGTX and JPM and KO?

These companies operate in different sectors (VSTM (Healthcare) and TGTX (Healthcare) and JPM (Financial Services) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: VSTM is a small-cap high-growth stock; TGTX is a small-cap high-growth stock; JPM is a large-cap deep-value stock; KO is a large-cap quality compounder stock. JPM, KO pay a dividend while VSTM, TGTX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.